{"type":"trials","record":{"id":34812,"source_id":"clinicaltrials-gov","external_id":"NCT03675724","title":"Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults","brief_summary":"This is a pilot study to test the efficacy of the anti-inflammatory drug (Fisetin) in reducing inflammatory factors in blood in elderly adults and to test the efficacy of the drug (Fisetin) in reducing frailty and markers of inflammation, insulin resistance, and bone resorption in elderly adults.","overall_status":"Enrolling By Invitation","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Mayo Clinic","enrollment":40,"countries":["United States"],"start_date":"2018-11-15","completion_date":"2027-11-01","last_update_date":"2026-05-22","source_url":"https://clinicaltrials.gov/study/NCT03675724","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Enrolling By Invitation. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:20:20.087268+00:00","last_seen_at":"2026-09-25T06:10:07.378+00:00","metadata":{"sex":"ALL","acronym":"AFFIRM-LITE","age_range":"70 Years","comparator":"Placebo","organization":"Mayo Clinic","interventions":["Fisetin","Placebo oral capsule"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Decrease in blood inflammation markers — Seven Days"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · DOUBLE","source_has_results":false},"controlled_terms":["Frail Elderly Syndrome","Fisetin","Placebo oral capsule"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: frailty.","quality_checked_at":"2026-09-25T06:10:20.034853+00:00","duplicate_cluster_key":"id:nct03675724","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2018-11-15 to 2027-11-01","comparator":"Placebo","confidence":"structured-source","population":"ALL · 70 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:10:07.430Z","intervention":["Fisetin","Placebo oral capsule"],"participants":40,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · DOUBLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Decrease in blood inflammation markers — Seven Days"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"frailty","is_published":true,"match_reasons":["Title contains controlled term: frailty.","Abstract contains controlled term: frailty.","Title supplies longevity context: frailty, frail.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Frailty","slug":"frailty"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/34812","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}